The Reagan-Udall Foundation for the FDA is facilitating an effort to explore actionable strategies for improving the clarity, consistency, and efficiency of oncology multi-regional clinical trials (MRCTs). The project will address challenges to timely site activation and patient enrollment, opportunities to address regulatory and operational barriers through technology and trial modernization (including U.S. community based trials), and examining intrinsic (e.g., patient population, site selection) and extrinsic (e.g., standard of care, data fidelity, generalizability) factors that affect trial design and execution. The project will culminate in a public report released in early November, with the goal of advancing opportunities for multi-regional scientific investigation and informing future regulatory and operational improvements.